Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180392
Title: | Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 |
Author: | Buxeda, Anna Arias Cabrales, Carlos Pérez Sáez, María José Cacho, Judit Cabello Pelegrin, Sheila Melilli, Edoardo Aladrén, María José Galeano, Cristina Lorenzo, Inmaculada Mazuecos, Auxiliadora Saura, Isabel María Franco, Antonio Ruiz Fuentes, María Del Carmen Sánchez Cámara, Luis Alberto Siverio, Orlando Martin, María Luisa González García, Elena López, Verónica Martin Moreno, Paloma Leticia Moina, Iñigo Moral Berrio, Esperanza Moreso, Francesc Portolés, José Santana Estupiñán, Raquel Zárraga, Sofía Canal, Cristina Sánchez Álvarez, Emilio Pascual, Julio (Pascual Santos) Crespo, Marta |
Keywords: | SARS-CoV-2 Trasplantament renal SARS-CoV-2 Kidney transplantation |
Issue Date: | 1-Sep-2021 |
Publisher: | Elsevier BV |
Abstract: | Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ekir.2021.06.023 |
It is part of: | Kidney International Reports, 2021, vol. 6, num. 9, p. 2305-2315 |
URI: | http://hdl.handle.net/2445/180392 |
Related resource: | https://doi.org/10.1016/j.ekir.2021.06.023 |
ISSN: | 2468-0249 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS2468024921012791.pdf | 703.64 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License